Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy

Inclusion criteria: Patient with non-ST-segment elevation Acute Coronary Syndrome (NSTE-ACS) with:

1. Ischemic symptoms (chest pain or equivalent) at rest ≥ 10 minutes within 24 hours ofrandomization, AND

2. One of the two following criteria:

• New ST-segment depression ≥ 0.1 mV (≥1 mm), or transient (< 30 minutes)ST-segment elevation ≥ 0.1 mV (≥ 1 mm) in at least 2 contiguous leads on theelectrocardiogram,

• Elevation of cardiac biomarkers within 24 hours of randomization, defined aselevated troponin T, troponin I, or CK-MB level above upper limit of normal, AND

3. Planned to have a coronary angiography (followed, when indicated, by PCI) as early aspossible (after at least 2 hours of treatment with study drug) and within 36 hours (atthe latest on Day 3, if justified), AND

4. Informed consent obtained in writing.

Exclusion criteria:

• Revascularization procedure already performed for the qualifying event AcuteST-segment elevation MI.

• Patient having received curative dose of anticoagulant treatment (including UFH, LMWH,or bivalirudin) for more than 24 hours prior to randomization or who have been treatedby abciximab.

• Inability to discontinue current anticoagulation in order to transition toInvestigational Products according to the specified transition timing.

• Patient who can not be treated by aspirin and clopidogrel (or any other oralantiplatelet agent) according to their local labeling.

• Patient who cannot be treated with eptifibatide according to the national labeling (when available). In countries where eptifibatide is not approved the reference labelto be considered is either the European labeling or the US labeling

• Patient who cannot be treated with unfractionated heparin according to the nationallabeling.

• Allergy to otamixaban. The above information is not intended to contain all considerations relevant to a patient'spotential participation in a clinical trial.